Despite the hazards of immune-related cutaneous adverse events (irCAEs), some studies suggest that patients with irCAEs may benefit more from treatment with PD-1/PD-L1 checkpoint inhibitors17,18; however, the extent to which these results can be extrapolated to all tumour types remains unclear. This evidence concerns the gene PDCD1 and neoplasm.